RESUMO
OBJECTIVE: To determine the safety, immunogenicity, and efficacy of revaccination of children with live attenuated influenza vaccine. STUDY DESIGN: A 2-year multicenter, double-blind, placebo-controlled, efficacy field trial of live attenuated, cold-adapted trivalent influenza vaccine administered by nasal spray to children. This report summarizes year 2 results, a year in which the epidemic strain of influenza A/Sydney was not well matched to the vaccine strains. Each year, vaccine strains were antigenically equivalent to the contemporary inactivated influenza vaccine. In year 2, a single intranasal revaccination was administered. Active surveillance for influenza was conducted during the influenza season by means of viral cultures. Influenza cases were defined as illnesses with wild-type influenza virus isolated from respiratory secretions. RESULTS: In year 2, 1358 (85%) children, 26 to 85 months of age, returned for revaccination. The intranasal vaccine was easily accepted, well tolerated, and immunogenic. Revaccination resulted in 82% to 100% of the vaccinated children in a subset studied for immunogenicity being seropositive as compared with 26% to 65% of placebo recipients, depending on the influenza strain tested. No serious adverse events were associated with the vaccine. In addition to the strains in the vaccine, antibody was induced to the variant strain A/Sydney/H3N2. In year 2, influenza A/Sydney/H3N2, a variant not contained in the vaccine, caused 66 of 70 cases of influenza A; nonetheless, intranasal vaccine was 86% efficacious in preventing A/Sydney influenza. Eight cases of lower respiratory tract disease were associated with A/Sydney influenza; all cases were in the placebo group. CONCLUSIONS: This live attenuated, cold-adapted influenza vaccine was safe, immunogenic, and efficacious against influenza A/H3N2 (including a variant, A/Sydney, not contained in the vaccine) and influenza B. The characteristics of this vaccine make it suitable for routine use in children to prevent influenza.
Assuntos
Vírus da Influenza A/imunologia , Vacinas contra Influenza/administração & dosagem , Influenza Humana/prevenção & controle , Vacinação , Administração Intranasal , Criança , Pré-Escolar , Temperatura Baixa , Método Duplo-Cego , Feminino , Humanos , Vírus da Influenza B/imunologia , Masculino , Estudos Prospectivos , Vacinas AtenuadasRESUMO
OBJECTIVE: To evaluate the safety, immunogenicity, and immunologic memory in young infants of a seven-valent (6B, 14, 19F, 23F, 18C, 4, 9V) pneumococcal vaccine conjugated to the outer membrane protein complex of Neisseria meningitidis. VACCINEES: Healthy 2-month-old infants 12- to 15-month-old control infants were recruited from participating private practices. METHODS: Infants (n = 25) were vaccinated at 2, 4, and 6 months of age with the conjugated pneumococcal vaccine, followed by a single dose of licensed pneumococcal polysaccharide vaccine (n = 20) at 12 to 15 months of age. Thirteen infants who had not received the investigational pneumococcal conjugate vaccine served as control subjects and were given a single dose of the licensed pneumococcal polysaccharide vaccine at 12 to 15 months of age. RESULTS: The investigational pneumococcal conjugate vaccine was well tolerated by infants. The vaccine was highly immunogenic in young infants, with significant increases in antibody to all seven serotypes after either two or three injections. At 12 to 15 months of age, infants who had been primed with the investigational pneumococcal conjugate vaccine had a brisk immunologic response to the booster injection of the licensed pneumococcal polysaccharide vaccine. Control infants, who received a single primary injection of the licensed pneumococcal polysaccharide vaccine, had negligible immunologic responses to four of the seven serotypes and low responses to the other three types. CONCLUSION: The investigational seven-valent pneumococcal conjugate vaccine administered to young infants was well tolerated and highly immunogenic and provided immunologic memory to an injection of the licensed pneumococcal polysaccharide vaccine.
Assuntos
Proteínas da Membrana Bacteriana Externa/imunologia , Vacinas Meningocócicas , Infecções Pneumocócicas/imunologia , Vacinas Pneumocócicas , Polissacarídeos Bacterianos/imunologia , Vacinas Conjugadas/imunologia , Proteínas da Membrana Bacteriana Externa/efeitos adversos , Avaliação de Medicamentos , Ensaio de Imunoadsorção Enzimática , Vacina Pneumocócica Conjugada Heptavalente , Humanos , Lactente , Neisseria meningitidis , Polissacarídeos Bacterianos/efeitos adversos , Vacinas Conjugadas/efeitos adversosRESUMO
In a multicenter, randomized, investigator-blinded trial, patients were randomly selected to receive either cefpodoxime proxetil or amoxicillin-clavulanate potassium orally for the treatment of acute suppurative otitis media. Patients were seen before, during, and at the end of therapy, and 2 to 3 weeks after completion of therapy. A total of 229 patients, 153 receiving cefpodoxime and 76 receiving amoxicillin-clavulanate were entered into the study; all patients were examined to determine drug safety. A total of 146 patients, 98 in the cefpodoxime group and 48 in the amoxicillin-clavulanate group, completed the study and were examined to determine drug efficacy. End-of-therapy microbiologic eradication rates in assessable patients were 92% for cefpodoxime and 86% for amoxicillin-clavulanate (p = 0.14; 95% confidence interval (CI) on difference: -4.4%, 19.2%). End-of-therapy clinical response rates for assessable patients were as follows: cured, 68% for cefpodoxime and 65% for amoxicillin-clavulanate; improved, 24% for cefpodoxime and 23% for amoxicillin-clavulanate; and failed, 8% for cefpodoxime and 13% for amoxicillin-clavulanate (p = 0.57; 95% CI: -8.4%, 16.5%). Recurrence rates at long-term follow-up were 24% for cefpodoxime-treated patients and 25% for those given amoxicillin-clavulanate. Both drugs were well tolerated; 20.9% of those given cefpodoxime and 31.6% of amoxicillin-clavulanate-treated patients had drug-related adverse medical events (p = 0.102; 95% CI: -23.9%, 2.6%). Gastrointestinal complaints were the most frequently reported drug-related side effect in both groups: 11.8% of cefpodoxime-treated patients and 21.1% of those given amoxicillin-clavulanate (p = 0.076; 95% CI: -20.8%, 2.2%). Drug-related dermatologic side effects (e.g., diaper rash, pruritus, urticaria) were reported in 7.8% of cefpodoxime-treated patients and 14.5% of those who received amoxicillin-clavulanate (p = 0.160; 95% CI: -16.6%, 3.3%). Our findings suggest that clinical efficacy for cefpodoxime administered twice daily is equivalent to that of amoxicillin-clavulanate administered three times a day.
Assuntos
Amoxicilina/uso terapêutico , Ceftizoxima/análogos & derivados , Otite Média Supurativa/tratamento farmacológico , Pró-Fármacos/uso terapêutico , Doença Aguda , Adolescente , Bactérias/isolamento & purificação , Ceftizoxima/efeitos adversos , Ceftizoxima/uso terapêutico , Criança , Pré-Escolar , Orelha/microbiologia , Feminino , Humanos , Lactente , Masculino , Otite Média Supurativa/microbiologia , Pró-Fármacos/efeitos adversos , Resultado do Tratamento , Cefpodoxima ProxetilAssuntos
Proteínas da Membrana Bacteriana Externa/administração & dosagem , Vacinas Bacterianas/administração & dosagem , Vacinas Anti-Haemophilus , Imunização Secundária , Polissacarídeos Bacterianos/administração & dosagem , Vacinas Sintéticas/administração & dosagem , Haemophilus influenzae , Humanos , Lactente , Neisseria meningitidisRESUMO
Infant botulism is confirmed by isolation of Clostridium botulinum from stool culture or by toxin assay. Although electrodiagnosis has been described as a diagnostic tool in infant botulism, our 11-year review of toxin-confirmed cases suggests that electrodiagnosis is not a reliable tool. In the case report presented, results of electrodiagnosis were negative but enema effluent contained adequate concentrations of organism and toxin to confirm the diagnosis.
Assuntos
Botulismo/diagnóstico , Eletrodiagnóstico , Toxinas Botulínicas/análise , Botulismo/epidemiologia , Clostridium botulinum/isolamento & purificação , Fezes/microbiologia , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Junção Neuromuscular/fisiologia , Reprodutibilidade dos Testes , Estudos Retrospectivos , Transmissão Sináptica/fisiologiaRESUMO
Pathogenic bacteria were isolated from 90% of patients with acute otitis media. This higher-than-expected rate of positive cultures was probably related to the meticulous bacteriologic techniques used.
Assuntos
Bactérias/isolamento & purificação , Otite Média/microbiologia , Doença Aguda , Adolescente , Amoxicilina/uso terapêutico , Combinação Amoxicilina e Clavulanato de Potássio , Técnicas Bacteriológicas , Cefixima , Cefotaxima/análogos & derivados , Cefotaxima/uso terapêutico , Ceftizoxima/análogos & derivados , Ceftizoxima/uso terapêutico , Cefalosporinas/uso terapêutico , Criança , Pré-Escolar , Ácidos Clavulânicos/uso terapêutico , Quimioterapia Combinada/uso terapêutico , Haemophilus influenzae/isolamento & purificação , Humanos , Lactente , Moraxella catarrhalis/isolamento & purificação , Otite Média/tratamento farmacológico , Otite Média/patologia , Pró-Fármacos/uso terapêutico , Punções , Recidiva , Método Simples-Cego , Streptococcus pneumoniae/isolamento & purificação , Membrana Timpânica/microbiologia , Membrana Timpânica/patologia , Cefpodoxima ProxetilRESUMO
We questioned if PBP analysis could differentiate strains of Haemophilus influenzae, H. aegyptius, and H. influenzae biogroup aegyptius associated with Brazilian Purpuric Fever. A relatively homogeneous PBP pattern was observed for all strains. The amount of penicillin bound to PBP 5 appeared to separate H. influenzae and H. aegyptius isolates, whereas PBP 5 of those strains associated with Brazilian Purpuric Fever bound an intermediate amount. We conclude that based on PBP profiles, the strains tested appear to be difficult to separate taxonomically and may represent a common species.